Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -2.9x - -3.2x | -3.1x |
| Selected Fwd P/E Multiple | -2.1x - -2.3x | -2.2x |
| Fair Value | $14.72 - $16.27 | $15.49 |
| Upside | 1.4% - 12.0% | 6.7% |
| Benchmarks | - | Full Ticker |
| Curis, Inc. | - | NasdaqCM:CRIS |
| I-Mab | - | NasdaqGM:IMAB |
| XOMA Royalty Corporation | - | NasdaqGM:XOMA |
| INmune Bio, Inc. | - | NasdaqCM:INMB |
| Spero Therapeutics, Inc. | - | NasdaqGS:SPRO |
| Neurogene Inc. | - | NasdaqGM:NGNE |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| CRIS | IMAB | XOMA | INMB | SPRO | NGNE | |||
| NasdaqCM:CRIS | NasdaqGM:IMAB | NasdaqGM:XOMA | NasdaqCM:INMB | NasdaqGS:SPRO | NasdaqGM:NGNE | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 8.5% | 95.2% | 58.3% | -40.2% | -400.6% | -650.3% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -420.3% | -3504.4% | -227.9% | -58154.1% | -408.4% | -6342.3% | ||
| Prior Fiscal Year | -557.7% | 1131.6% | -973.2% | -19360.0% | -86.7% | NA | ||
| Latest Fiscal Year | -473.0% | -5302.0% | -67.7% | -300585.7% | 22.0% | -8123.7% | ||
| Latest Twelve Months | -443.3% | -15495.7% | -67.7% | -300585.7% | 3.3% | -8123.7% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | -0.8x | 1.8x | -7.1x | NA | 0.1x | 1.0x | ||
| Price / LTM Sales | 1.8x | 120.3x | 8.5x | 12316.9x | 0.9x | 234.4x | ||
| LTM P/E Ratio | -0.5x | -0.8x | -12.6x | -4.1x | -0.6x | -2.9x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -12.6x | -0.8x | -0.5x | |||||
| Historical LTM P/E Ratio | -4.9x | -3.9x | -2.9x | |||||
| Selected P/E Multiple | -2.9x | -3.1x | -3.2x | |||||
| (x) LTM Net Income | (75) | (75) | (75) | |||||
| (=) Equity Value | 219 | 230 | 242 | |||||
| (/) Shares Outstanding | 14.9 | 14.9 | 14.9 | |||||
| Implied Value Range | 14.65 | 15.42 | 16.19 | |||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 14.65 | 15.42 | 16.19 | 14.52 | ||||
| Upside / (Downside) | 0.9% | 6.2% | 11.5% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | CRIS | IMAB | XOMA | INMB | SPRO | NGNE | |
| Value of Common Equity | 20 | 69 | 244 | 172 | 43 | 217 | |
| (/) Shares Outstanding | 8.5 | 81.4 | 12.0 | 22.9 | 55.9 | 14.9 | |
| Implied Stock Price | 2.32 | 0.84 | 20.33 | 7.52 | 0.77 | 14.52 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 2.32 | 0.84 | 20.33 | 7.52 | 0.77 | 14.52 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |